Clinical Trial Update: Evaluation of the Prophylactic Use of Mitomycin C 0.02% to Inhibit Haze Formation After Photorefractive Keratectomy for High Myopia: 15 x 30 Seconds [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating prophylactic 0.02% mitomycin C eye drops to prevent haze after photorefractive keratectomy for high myopia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High Myopia

Drugs mentioned

• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Instituto de Olhos de Goiania | Conditions: High Myopia | Phase 4 | Status: COMPLETED